(Q37737291)

22 August 2017

1 reference

title

Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression (English)

1 reference

22 August 2017

William V Bobo

1

1 reference

22 August 2017

Richard C Shelton

series ordinal

2

1 reference

22 August 2017

publication date

1 May 2010

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

22 August 2017

published in

1 reference

22 August 2017

volume

10

1 reference

22 August 2017

issue

5

1 reference

22 August 2017

page(s)

651-670

1 reference

One-month prevalence of mental disorders in the United States. Based on five Epidemiologic Catchment Area sites

22 August 2017

cites work

1 reference

The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)

21 January 2018

1 reference

Sex and depression in the National Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence

21 January 2018

1 reference

Sex differences in rates of depression: cross-national perspectives

21 January 2018

1 reference

Global burden of depressive disorders in the year 2000

21 January 2018

1 reference

The course, morbidity, and costs of depression

21 January 2018

1 reference

Service utilization and social morbidity associated with depressive symptoms in the community.

21 January 2018

1 reference

Depression, chronic diseases, and decrements in health: results from the World Health Surveys.

21 January 2018

1 reference

Depression and public health

21 January 2018

1 reference

Medical co-morbidity in depressive disorders.

21 January 2018

1 reference

Disability in major depression related to self-rated and objectively-measured cognitive deficits: a preliminary study

21 January 2018

1 reference

Predictors of long-term work disability in Major Depressive Disorder: a prospective study

21 January 2018

1 reference

Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse.

21 January 2018

1 reference

Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report.

21 January 2018

1 reference

Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness?

21 January 2018

1 reference

A prospective follow-up of patients with bipolar and primary unipolar affective disorder.

21 January 2018

1 reference

Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice

21 January 2018

1 reference

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

21 January 2018

1 reference

Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.

21 January 2018

1 reference

A rating scale for depression

21 January 2018

1 reference

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

21 January 2018

1 reference

The role and clinical significance of subsyndromal depressive symptoms (SSD) in unipolar major depressive disorder

21 January 2018

1 reference

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

21 January 2018

1 reference

Outcomes in major depressive disorder: the evolving concept of remission and its implications for treatment

21 January 2018

1 reference

Nonresponse, partial response, and failure to achieve remission: humanistic and cost burden in major depressive disorder

21 January 2018

1 reference

What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials

21 January 2018

1 reference

Diagnosis and definition of treatment-resistant depression

21 January 2018

1 reference

Identifying difficult-to-treat depression: differential diagnosis, subtypes, and comorbidities

21 January 2018

1 reference

Medication augmentation after the failure of SSRIs for depression.

21 January 2018

1 reference

A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report

21 January 2018

1 reference

Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report.

21 January 2018

1 reference

A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report

21 January 2018

1 reference

Predictors of response to antidepressants general principles and clinical implications

21 January 2018

1 reference

Functioning and interpersonal relationships as predictors of response in treatment-resistant depression.

21 January 2018

1 reference

Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches

21 January 2018

1 reference

Switching Antidepressants After a First Selective Serotonin Reuptake Inhibitor in Major Depressive Disorder

21 January 2018

1 reference

Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder

21 January 2018

1 reference

Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials

21 January 2018

1 reference

The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

Efficacy and tolerability of adjunctive ziprasidone in treatment-resistant depression: a randomized, open-label, pilot study

21 January 2018

1 reference

Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression

21 January 2018

1 reference

Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics

21 January 2018

1 reference

Binding of antidepressants to human brain receptors: focus on newer generation compounds

21 January 2018

1 reference

Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors

21 January 2018

1 reference

Mechanisms underlying psychosis and antipsychotic treatment response in schizophrenia: insights from PET and SPECT imaging.

21 January 2018

1 reference

Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds

21 January 2018

1 reference

The role of serotonin in antipsychotic drug action

21 January 2018

1 reference

Olanzapine. Pharmacokinetic and pharmacodynamic profile.

21 January 2018

1 reference

Modulation of noradrenergic neuronal firing by selective serotonin reuptake blockers

21 January 2018

1 reference

Functional and pharmacological characterization of the modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neurons

21 January 2018

1 reference

Selective serotonin reuptake inhibitors reduce the spontaneous activity of dopaminergic neurons in the ventral tegmental area

21 January 2018

1 reference

Selective blockade of serotonin-2C/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study

21 January 2018

1 reference

Selective blockade of serotonin2C/2B receptors enhances dopamine release in the rat nucleus accumbens

21 January 2018

1 reference

SB 242084, a selective serotonin2C receptor antagonist, increases dopaminergic transmission in the mesolimbic system

21 January 2018

1 reference

Fluoxetine administration potentiates the effect of olanzapine on locus coeruleus neuronal activity

21 January 2018

1 reference

5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release

21 January 2018

1 reference

5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner

21 January 2018

1 reference

Role for dopamine in the behavioral functions of the prefrontal corticostriatal system: implications for mental disorders and psychotropic drug action

21 January 2018

1 reference

Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects

21 January 2018

1 reference

Variation in brain-derived neurotrophic factor (BDNF) gene is associated with symptoms of depression

21 January 2018

1 reference

Neuronal plasticity and survival in mood disorders.

21 January 2018

1 reference

A neurotrophic model for stress-related mood disorders

21 January 2018

1 reference

Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications

21 January 2018

1 reference

Future Antidepressant Targets: Neurotrophic Factors and Related Signaling Cascades

21 January 2018

1 reference

Pharmacologically diverse antidepressants rapidly activate brain-derived neurotrophic factor receptor TrkB and induce phospholipase-Cgamma signaling pathways in mouse brain

21 January 2018

1 reference

Role of neurotrophic factors in depression

21 January 2018

1 reference

Post-stress changes in BDNF and Bcl-2 immunoreactivities in hippocampal neurons: effect of chronic administration of olanzapine

21 January 2018

1 reference

Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness

21 January 2018

1 reference

Clinical pharmacokinetics of fluoxetine

21 January 2018

1 reference

Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients.

21 January 2018

1 reference

Pharmacokinetics of selective serotonin reuptake inhibitors

21 January 2018

1 reference

Serum concentrations of fluoxetine in the clinical treatment setting

21 January 2018

1 reference

Influence of fluoxetine on olanzapine pharmacokinetics

21 January 2018

1 reference

Effects of age and sex on olanzapine plasma concentrations

21 January 2018

1 reference

Fluoxetine pharmacokinetics and effect on CYP2C19 in young and elderly volunteers

21 January 2018

1 reference

Biotransformation of Post-Clozapine Antipsychotics

21 January 2018

1 reference

Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update

21 January 2018

1 reference

Potential medical and surgical complications of serotonergic antidepressant medications

21 January 2018

1 reference

Interaction between selective serotonin reuptake inhibitors and nonsteroidal antiinflammatory drugs: review of the literature

21 January 2018

1 reference

A novel augmentation strategy for treating resistant major depression

21 January 2018

1 reference

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression

21 January 2018

1 reference

A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder

21 January 2018

1 reference

A rating scale for drug-induced akathisia

21 January 2018

1 reference

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

21 January 2018

1 reference

First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis

21 January 2018

1 reference

The incidence of diabetes in atypical antipsychotic users differs according to agent--results from a multisite epidemiologic study.

21 January 2018

1 reference

Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment

21 January 2018

1 reference

Depression as a risk factor for cardiac mortality and morbidity: a review of potential mechanisms

21 January 2018

1 reference

Augmentation with olanzapine in TCA-refractory depression with melancholic features: a consecutive case series

21 January 2018

1 reference

Creating more effective antidepressants: clues from the clinic

21 January 2018

1 reference

Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues

21 January 2018

1 reference

Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study

21 January 2018

1 reference

The atypical antipsychotics olanzapine and risperidone in the treatment of posttraumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials

21 January 2018

1 reference

A 24-Week Open-Label Extension Study of Olanzapine-Fluoxetine Combination and Olanzapine Monotherapy in the Treatment of Bipolar Depression

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERN.10.44

1 reference

22 August 2017

1 reference